CCA
CVKD icon

Cygnus Capital Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

Cygnus Capital Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8 Buy
+1,492
New +$10.5K 0.01% 99

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $709M AUM 19.96% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Cygnus Capital Advisors's CVKD Position: Q1 2026 in Review

Cygnus Capital Advisors opened a new position in Cadrenal Therapeutics (CVKD) in Q1 2026: 1,492 shares worth $8. The stake represents 0.01% of the portfolio and ranks #99 among its holdings.

20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • Cygnus Capital Advisors held 1,492 shares of Cadrenal Therapeutics worth $8 as of Q1 2026.
  • Cadrenal Therapeutics was a new Cygnus Capital Advisors position in Q1 2026.
  • Cadrenal Therapeutics made up 0.01% of Cygnus Capital Advisors's portfolio in Q1 2026, its #99 holding.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.